Healthcare provider profile · identity verified

John N Kersteff, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · PLAINFIELD, IN · NPI 1942295936

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John N Kersteff, M.D. received $51.43 in general payments during 2025 across 2 reported records.

Abbott Laboratories accounted for 63.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$51.43

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Abbott Laboratories	Unresolved — no canonical attribution shown	$32.63	63.5%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$18.80	36.5%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$51.43	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CARDIOMEMS Normalized: cardiomems	Device	Abbott Laboratories	$32.63	1	2025
Source payment records 2025-12-14 · Abbott Laboratories · $32.63 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$18.80	1	2025
Source payment records 2025-08-26 · Lilly USA, LLC · $18.80 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$18.80	1	2025
Source payment records 2025-08-26 · Lilly USA, LLC · $18.80 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	76	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	53	12
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	76	17
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	57	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	675	185
Pantoprazole Sodium	Pantoprazole Sodium	415	120
Amlodipine Besylate	Amlodipine Besylate	414	111
Lisinopril	Lisinopril	352	97
Levothyroxine Sodium	Levothyroxine Sodium	347	89
Metoprolol Succinate	Metoprolol Succinate	341	92
Gabapentin	Gabapentin	326	77
Tamsulosin Hcl	Tamsulosin Hcl	324	94
Omeprazole	Omeprazole	280	79
Glimepiride	Glimepiride	254	70
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	240	73
Rosuvastatin Calcium	Rosuvastatin Calcium	213	69
Prednisone	Prednisone	199	130
Famotidine	Famotidine	193	54
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	190	55
Simvastatin	Simvastatin	187	53
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	183	49
Meloxicam	Meloxicam	181	59
Valsartan	Valsartan	172	52
Alprazolam	Alprazolam	170	40
Tramadol Hcl	Tramadol Hcl	168	42
Metformin Hcl	Metformin Hcl	165	46
Celecoxib	Celecoxib	164	47
Losartan Potassium	Losartan Potassium	163	48
Pravastatin Sodium	Pravastatin Sodium	154	43
Metoprolol Tartrate	Metoprolol Tartrate	146	40
Escitalopram Oxalate	Escitalopram Oxalate	141	37
Hydrochlorothiazide	Hydrochlorothiazide	141	44
Furosemide	Furosemide	136	36
Trazodone Hcl	Trazodone Hcl	135	33
Allopurinol	Allopurinol	127	33
Albuterol Sulfate Hfa	Albuterol Sulfate	120	28
Spironolactone	Spironolactone	116	35
Naproxen	Naproxen	115	36
Sertraline Hcl	Sertraline Hcl	106	31
Duloxetine Hcl	Duloxetine Hcl	105	25
Clopidogrel	Clopidogrel Bisulfate	100	28
Eliquis	Apixaban	100	18
Alendronate Sodium	Alendronate Sodium	99	28
Potassium Chloride	Potassium Chloride	99	29
Fluoxetine Hcl	Fluoxetine Hcl	97	29
Bupropion Xl	Bupropion Hcl	88	25
Carvedilol	Carvedilol	84	24
Nifedipine Er	Nifedipine	84	23
Clonazepam	Clonazepam	82	22
Ozempic	Semaglutide	80	14
Warfarin Sodium	Warfarin Sodium	80	14
Klor-Con M20	Potassium Chloride	78	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	77	19
Mounjaro	Tirzepatide	76	17
Ezetimibe	Ezetimibe	73	19
Montelukast Sodium	Montelukast Sodium	73	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	69	13
Fenofibrate	Fenofibrate	68	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	67	19
Tizanidine Hcl	Tizanidine Hcl	65	21
Venlafaxine Hcl Er	Venlafaxine Hcl	65	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	63	51
Clonidine Hcl	Clonidine Hcl	63	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	62	19
Chlorthalidone	Chlorthalidone	61	18
Zolpidem Tartrate	Zolpidem Tartrate	59	19
Donepezil Hcl	Donepezil Hcl	58	20
Trulicity	Dulaglutide	57	suppressed
Jardiance	Empagliflozin	53	12
Olmesartan Medoxomil	Olmesartan Medoxomil	52	15
Breo Ellipta	Fluticasone/Vilanterol	50	suppressed
Ondansetron Odt	Ondansetron	49	22
Fluticasone Propionate	Fluticasone Propionate	48	18
Triamcinolone Acetonide	Triamcinolone Acetonide	48	36
Fenofibrate	Fenofibrate Nanocrystallized	46	13
Dutasteride	Dutasteride	44	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	42	12
Pioglitazone Hcl	Pioglitazone Hcl	42	12
Lansoprazole	Lansoprazole	41	11
Metformin Hcl Er	Metformin Hcl	39	12
Paroxetine Hcl	Paroxetine Hcl	39	suppressed
Januvia	Sitagliptin Phosphate	38	suppressed
Methylprednisolone	Methylprednisolone	38	29
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	38	suppressed
Propranolol Hcl Er	Propranolol Hcl	38	11
Synthroid	Levothyroxine Sodium	36	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	35	suppressed
Glyburide-Metformin Hcl	Glyburide/Metformin Hcl	35	11
Irbesartan	Irbesartan	35	suppressed
Pregabalin	Pregabalin	35	suppressed
Ventolin Hfa	Albuterol Sulfate	35	suppressed
Amoxicillin	Amoxicillin	33	28
Bupropion Hcl Sr	Bupropion Hcl	33	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	33	suppressed
Estradiol	Estradiol	33	suppressed
Memantine Hcl	Memantine Hcl	33	suppressed
Azithromycin	Azithromycin	32	28
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	32	28
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	30	suppressed
Atenolol	Atenolol	30	suppressed
Finasteride	Finasteride	30	suppressed
Ibuprofen	Ibuprofen	30	suppressed
Lorazepam	Lorazepam	30	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	30	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	29	suppressed
Glipizide Er	Glipizide	29	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	27	12
Mirtazapine	Mirtazapine	27	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	17
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Cephalexin	Cephalexin	23	19
Nitroglycerin	Nitroglycerin	23	15
Tradjenta	Linagliptin	23	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Ipratropium Bromide	Ipratropium Bromide	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	21	suppressed
Diazepam	Diazepam	19	suppressed
Topiramate	Topiramate	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Aripiprazole	Aripiprazole	18	suppressed
Fluconazole	Fluconazole	18	13
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Doxepin Hcl	Doxepin Hcl	17	suppressed
Glipizide	Glipizide	17	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	17	suppressed
Baclofen	Baclofen	16	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	16	suppressed
Gemfibrozil	Gemfibrozil	16	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Theophylline Er	Theophylline Anhydrous	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Torsemide	Torsemide	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Propranolol Hcl	Propranolol Hcl	14	suppressed
Risperidone	Risperidone	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Dulera	Mometasone/Formoterol	13	suppressed
Glycopyrrolate	Glycopyrrolate	13	suppressed
Guanfacine Hcl Er	Guanfacine Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	13	suppressed
Desloratadine	Desloratadine	12	suppressed
Niacin Er	Niacin	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Primidone	Primidone	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Vascepa	Icosapent Ethyl	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$51.43 · 2 records	Abbott Laboratories	CARDIOMEMS, MOUNJARO, ZEPBOUND	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error